WO2020127887A1 - Process for the preparation of an intermediate product of ivosidenib - Google Patents
Process for the preparation of an intermediate product of ivosidenib Download PDFInfo
- Publication number
- WO2020127887A1 WO2020127887A1 PCT/EP2019/086549 EP2019086549W WO2020127887A1 WO 2020127887 A1 WO2020127887 A1 WO 2020127887A1 EP 2019086549 W EP2019086549 W EP 2019086549W WO 2020127887 A1 WO2020127887 A1 WO 2020127887A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- isonitrile
- uorocy
- preparing
- difluorocyclobutyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
- C07C291/10—Isocyanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C263/00—Preparation of derivatives of isocyanic acid
Definitions
- the present invention is directed to a process for the preparation of (3,3-difluorocyclo- butyl)isonitrile, an intermediate product in the synthesis of ivosidenib.
- the intermediate product (3,3-difluorocyclobutyl)isonitrile is prepared from A -(3 , 3 -di fl uorocy cl ob uty 1 )form a i de in dichloromethane using PPh3 and CCU and TEA (triethylamine) and is subsequently purified by filtration and column chromatography.
- This process for preparing (3,3-difluorocyclobutyl)isonitrile has several disadvantages. Several byproducts are formed so that the (3,3-difluorocyclobutyl)isonitrile needs to be purified by filtration and column chromatography. However, purification by column chromatography is expensive, cumbersome, and not suitable for the purification of an intermediate product in large scale production. Furthermore, PPh3 and CCU are not environmentally friendly and their use causes significant regulatory burden. Furthermore, the use of PPI13 poses several problems. First, PPI13 needs to be added as a solid under N2 atmosphere. Second, PPh3 byproducts are difficult to remove during the purification process.
- the present invention relates to the use of propylphosphonic acid anhydride (III) for preparing a compound according to formulae (2), (3) and/or (4).
- the present invention relates to a process for preparing the compound of formula (3) comprising the steps
- the present invention relates to a process for preparing ivosidenib according to formula (4) comprising the step
- Aprotic solvents are usually solvents that do not readily donate H + ions under reaction conditions in the presence of the tertiary amine base, i.e. the pK a of the solvent is at least 20.
- aprotic solvents comprise aliphatic, aromatic, ether, amide and ester solvents.
- Non-limiting examples of aprotic solvents comprise pentane, hexane, benzene, toluene, chloroform, DCM (di chi orom ethane), diethyl ether, 1,2-dimethoxy ether, MTBE (methyl -/t V-butyl ether), 1,4-dioxane, THF (tetrahydrofuran), MTHF (methyl- tetrahydrofuran), EtOAc (ethyl acetate), acetonitrile, DMF (A) A-di methyl form amide), DMA (A) A -di m ethyl acetam i de), DMSO (dimethylsulfoxide), and mixtures thereof.
- DCM di chi orom ethane
- diethyl ether 1,2-dimethoxy ether
- MTBE methyl -/t V-butyl ether
- Tertiary amine bases usually are hindered amines that contain three substituents independently selected from alkyl and aryl substituents.
- the term“tertiary amine” also refers to secondary cyclic amines and alkali metal acetate. These hindered amines act as a base, but do not act as nucleophiles due to steric hindrance.
- Non-limiting examples of tertiary amines comprise triethylamine, tributyl- amine, DIPEA ( N , A -di -/.vo-propy 1 ethyl am i ne), DBU (l,8-diazabicyclo[5.4.0]undec-7- ene), TBD (l,5,7-triazabicyclo(4.4.0)dec-5-ene), MTBD (7-methyl-l,5,7-triazabi- cyclo(4.4.0)dec-5-ene), DBN (l,5-diazabicyclo[4.3.0]non-5-ene), TMP (2,2,6,6-tetra- methylpiperidine), DABCO (l,4-diazabicyclo[2.2.2]octane), quinuclidine, and mixtures thereof.
- Propylphosphonic acid anhydride also called //-propylphosphonic anhydride
- T3P ® is usually supplied as 50 vol-% solution in various aprotic solvents under the trade mark T3P ® .
- step (b) comprises the steps of
- step (b) comprises the steps of (bT) adding the propylphosphonic acid anhydride (III) to the A -(3 , 3 -di fl uorocy cl o- butyl)formamide according to formula (1) in an aprotic solvent (I) and subsequently,
- the propylphosphonic acid anhydride (III) and the tertiary amine base (II) may be added in pure, undiluted form or as solution in a suitable aprotic solvent.
- the tertiary amine base (II) is selected from triethylamine, DIPEA, DBU, DABCO, quinuclidine and mixtures thereof. In a preferred embodiment, the tertiary amine base (II) is selected from triethylamine, DIPEA and mixtures thereof.
- the aprotic solvent (I) is a polar solvent.
- the aprotic solvent (I) is selected from EtOAc, THF, acetonitrile, 1,4-dioxane, DMF, DMA and mixtures thereof.
- the aprotic solvent is EtOAc.
- the process may be performed at room temperature.
- room temperature or ambient temperature is to be understood to encompass temperatures from 15°C to 30°C.
- step (b) further comprises: adding the at least one tertiary amine base (II) and/or the propylphosphonic acid anhydride (III) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) at a temperature Ti selected from -78°C to 30°C and subsequently heating the mixture to T2 selected from above 30°C to 77°C.
- step (b) further comprises: adding the at least one tertiary amine base (II) and/or the propylphosphonic acid anhydride (III) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) at a temperature Ti selected from 0°C to 30°C and subsequently heating the mixture to T2 selected from above 30°C to 77°C.
- step (b) further comprises: adding the at least one tertiary amine base (II) and/or the propylphosphonic acid anhydride (III) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form a i de according to formula (1) at a temperature Ti selected from 0°C to 30°C and subsequently heating the mixture to the boiling temperature of the aprotic solvent (I).
- temperature Ti is independently selected for the respective addition of the tertiary amine base (Ti a ) and the addition of the propylphosphonic acid anhydride (Tib).
- the skilled person will know how to select an appropriate temperature T2 for the heating so that the reaction is run to completion. If the heating temperature T2 is above the boiling temperature of the respective solvent, the reaction is performed under pressure. It is, however, preferred that the process is performed at ambient pressure.
- the process for preparing (3,3-difluorocyclo- butyl)isonitrile according to formula (2) comprises the steps:
- the process for preparing ivosidenib according to formula (4) comprises the steps
- This reaction can be referred to as a Ugi one-pot reaction.
- This reaction is a four component reaction (U-4CR), wherein the components comprise an aldehyde/ketone (2- chlorobenzaldehyde), an amine (3-amino-5-fluoropyridine), a carboxylic acid (L-pyro glutamic acid) and an isonitrile functional group ((3,3-difluorocyclobutyl)isonitrile).
- the purification in step (iii) comprises separating the diastereomers to obtain ivosidenib.
- suitable techniques such as high-performance liquid column chromatography (HPLC) or recrystallization from suitable solvents, to obtain ivosidenib as the desired diastereomer.
- the reaction in step (ii) with a compound selected from 2-bromo-4-cyano-pyridine, 4- cyano-2-fluoro-pyridine, 4-cyano-2-iodo-pyridine, and (4-cyano-2-pyridinyl)-trifluoro- methanesulfonate is a metal-catalyzed cross coupling reaction, e.g. a Buchwald- Hartwig coupling.
- Suitable reaction conditions, base, ligand and metal catalyst are known to the person skilled in the art.
- the metal catalyst is a palladium catalyst and that the ligand is a sterically hindered phosphine ligand, preferably a dialkylbiaryl phosphine, dppf (l, l'-bis(diphenylphosphino)ferrocene) or XantPhos ligand (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene). It is even more preferred that the metal catalyst is Pd 2 (dba) 3 and the ligand is XantPhos.
- the process for preparing the compound of formula (3) and the process for preparing ivosidenib according to formula (4) comprises the steps
- step (i) preparing (3,3-difluorocyclobutyl)isonitrile according to formula (2) by the process of the present invention and reacting the 3,3-difluorocyclobutyl)isonitrile according to formula (2) prepared in step (i) in-situ in step (ii) to obtain the compound of formula (3) in a one-pot process.
- step (i) and step (ii) are performed in the same reaction vessel and only the additional reactants needed in step (ii) are further added to the reaction vessel or the 3,3-difluorocyclobutyl)isonitrile prepared in step (i) is obtained as a crude product by routine work-up and directly used in step (ii) without further purification by e.g. filtration or column chromatography.
Abstract
The application relates to a process for preparing (3,3-difluorocyclobutyl)isonitrile of formula (2) comprising the steps of mixing N-(3,3-difluorocyclobutyl)formamide with an aprotic solvent and reacting the N-(3,3-difluorocyclobutyl)formamide with propylphosphonic acid anhydride in the presence of a tertiary amine base. The intermediate of formula (2) is used for the preparation of ivosidenib of formula (4).
Description
Process for the preparation of an intermediate product of ivosidenib
Field of the invention The present invention is directed to a process for the preparation of (3,3-difluorocyclo- butyl)isonitrile, an intermediate product in the synthesis of ivosidenib.
Background of the invention The preparation of ivosidenib, IUPAC name /V-[(lri)-l-(2-chlorophenyl)-2-[(3,3-di- fluorocyclobutyl)amino]-2-oxoethyl]-l-(4-cyanopyridin-2-yl)-/V-(5-fluoropyridin-3-yl)- 5-oxo-L-prolinamide, is known from WO 2013/107291. According to WO 2013/107291, the intermediate product (3,3-difluorocyclobutyl)isonitrile is prepared from A -(3 , 3 -di fl uorocy cl ob uty 1 )form a i de in dichloromethane using PPh3 and CCU and TEA (triethylamine) and is subsequently purified by filtration and column chromatography.
The chemical formulae (1), (2), (3), and (4) of A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de, (3,3-difluorocyclobutyl)isonitrile, A - J 1 -(2-chl orophenyl )-2-[(3 , 3 -di fl uorocy cl o- butyl )amino]-2-oxo-ethyl J-Af-(5-fluoro-3-pyridyl)-(S)-5-oxo-pyrrolidine-2-carboxamide and ivosidenib, respectively, are shown below as well as the process for preparing ivosidenib, as described in WO 2013/107291.
This process for preparing (3,3-difluorocyclobutyl)isonitrile has several disadvantages. Several byproducts are formed so that the (3,3-difluorocyclobutyl)isonitrile needs to be purified by filtration and column chromatography. However, purification by column chromatography is expensive, cumbersome, and not suitable for the purification of an intermediate product in large scale production. Furthermore, PPh3 and CCU are not environmentally friendly and their use causes significant regulatory burden. Furthermore, the use of PPI13 poses several problems. First, PPI13 needs to be added as a solid under N2 atmosphere. Second, PPh3 byproducts are difficult to remove during the purification process.
Therefore, it was an object of the present invention to provide an improved process for preparing (3,3-difluorocyclobutyl)isonitrile that is more cost efficient, requires fewer
starting materials, has a higher yield and does not require an additional purification step by filtration and column chromatography.
Summary of the invention
These objects have surprisingly been solved by the process according to the present invention for preparing (3,3-difluorocyclobutyl)isonitrile according to formula (2)
NC
(2)
comprising the steps:
(a) mixing A -(3 , 3 -di fl uorocy cl ob uty 1 )form a i de according to formula (1)
with an aprotic organic solvent (I), and (b) reacting the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) with propylphosphonic acid anhydride (III) in the presence of a tertiary amine base (II).
It has surprisingly been found that the use of propylphosphonic acid anhydride (III) in the presence of a tertiary amine base (II) overcomes the problems associated with the prior art process for preparing (3,3-difluorocyclobutyl)isonitrile. In particular, this new process omits the necessity for an additional purification step after the reaction is completed and the (3,3-difluorocyclobutyl)isonitrile can be used directly in the subsequent step of the synthesis of ivosidenib without purification or isolation. Additionally, the two-component system of solid PPh3 and liquid CCU is replaced by
one component, making the process more facile to handle. Even further, the process of the present invention results in improved yields over the prior art process.
In another embodiment, the present invention relates to the use of propylphosphonic acid anhydride (III) for preparing a compound according to formulae (2), (3) and/or (4).
In another embodiment, the present invention relates to a process for preparing the compound of formula (3) comprising the steps
(i) preparing (3,3-difluorocyclobutyl)isonitrile according to formula (2) by the process according to the present invention and
(ii) reacting the (3,3-difluorocyclobutyl)isonitrile according to formula (2) with 2- chlorobenzaldehyde, 3-amino-5-fluoropyridine, and L-pyroglutamic acid to obtain the compound according to formula (3).
In yet another embodiment, the present invention relates to a process for preparing ivosidenib according to formula (4) comprising the step
(i) preparing (3,3-difluorocyclobutyl)isonitrile according to formula (2) by the process according to the present invention.
Detailed description
The following definitions are relevant in connection with the embodiments of the present invention.
Aprotic solvents are usually solvents that do not readily donate H+ ions under reaction conditions in the presence of the tertiary amine base, i.e. the pKa of the solvent is at least 20. Preferably, aprotic solvents comprise aliphatic, aromatic, ether, amide and ester solvents. Non-limiting examples of aprotic solvents comprise pentane, hexane, benzene, toluene, chloroform, DCM (di chi orom ethane), diethyl ether, 1,2-dimethoxy ether, MTBE (methyl -/t V-butyl ether), 1,4-dioxane, THF (tetrahydrofuran), MTHF (methyl-
tetrahydrofuran), EtOAc (ethyl acetate), acetonitrile, DMF (A) A-di methyl form amide), DMA (A) A -di m ethyl acetam i de), DMSO (dimethylsulfoxide), and mixtures thereof.
Tertiary amine bases usually are hindered amines that contain three substituents independently selected from alkyl and aryl substituents. For the present invention, the term“tertiary amine” also refers to secondary cyclic amines and alkali metal acetate. These hindered amines act as a base, but do not act as nucleophiles due to steric hindrance. Non-limiting examples of tertiary amines comprise triethylamine, tributyl- amine, DIPEA ( N , A -di -/.vo-propy 1 ethyl am i ne), DBU (l,8-diazabicyclo[5.4.0]undec-7- ene), TBD (l,5,7-triazabicyclo(4.4.0)dec-5-ene), MTBD (7-methyl-l,5,7-triazabi- cyclo(4.4.0)dec-5-ene), DBN (l,5-diazabicyclo[4.3.0]non-5-ene), TMP (2,2,6,6-tetra- methylpiperidine), DABCO (l,4-diazabicyclo[2.2.2]octane), quinuclidine, and mixtures thereof.
Propylphosphonic acid anhydride, also called //-propylphosphonic anhydride, is usually supplied as 50 vol-% solution in various aprotic solvents under the trade mark T3P®.
Preferred embodiments according to the invention are defined hereinafter. The preferred embodiments are preferred alone or in combination. Further, it is to be understood that the following preferred embodiments refer to all aspects of the present invention, i.e. the process for preparing the compounds of formula (2), (3) or (4) and the use of propylphosphonic acid anhydride (III), if not specified otherwise.
In an embodiment, step (b) comprises the steps of
(bl) adding the tertiary amine base (II) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) in an aprotic solvent (I) and subsequently
(b2) adding the propylphosphonic acid anhydride (III).
In another embodiment, step (b) comprises the steps of
(bT) adding the propylphosphonic acid anhydride (III) to the A -(3 , 3 -di fl uorocy cl o- butyl)formamide according to formula (1) in an aprotic solvent (I) and subsequently,
(b2’) adding the tertiary amine base (II).
The propylphosphonic acid anhydride (III) and the tertiary amine base (II) may be added in pure, undiluted form or as solution in a suitable aprotic solvent.
In an embodiment, the tertiary amine base (II) is selected from triethylamine, DIPEA, DBU, DABCO, quinuclidine and mixtures thereof. In a preferred embodiment, the tertiary amine base (II) is selected from triethylamine, DIPEA and mixtures thereof.
In an embodiment, the aprotic solvent (I) is a polar solvent. In an embodiment, the aprotic solvent (I) is selected from EtOAc, THF, acetonitrile, 1,4-dioxane, DMF, DMA and mixtures thereof. In a preferred embodiment, the aprotic solvent is EtOAc.
The process may be performed at room temperature. The term room temperature or ambient temperature is to be understood to encompass temperatures from 15°C to 30°C.
In an embodiment, step (b) further comprises: adding the at least one tertiary amine base (II) and/or the propylphosphonic acid anhydride (III) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) at a temperature Ti selected from -78°C to 30°C and subsequently heating the mixture to T2 selected from above 30°C to 77°C.
In an embodiment, step (b) further comprises: adding the at least one tertiary amine base (II) and/or the propylphosphonic acid anhydride (III) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) at a temperature Ti selected from 0°C to 30°C and subsequently heating the mixture to T2 selected from above 30°C to 77°C.
In an embodiment, step (b) further comprises: adding the at least one tertiary amine base (II) and/or the propylphosphonic acid anhydride (III) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form a i de according to formula (1) at a temperature Ti selected from 0°C to 30°C and subsequently heating the mixture to the boiling temperature of the aprotic solvent (I).
In an embodiment, temperature Ti is independently selected for the respective addition of the tertiary amine base (Tia) and the addition of the propylphosphonic acid anhydride (Tib).
The skilled person will know how to select an appropriate temperature T2 for the heating so that the reaction is run to completion. If the heating temperature T2 is above the boiling temperature of the respective solvent, the reaction is performed under pressure. It is, however, preferred that the process is performed at ambient pressure.
In a more preferred embodiment, the process for preparing (3,3-difluorocyclo- butyl)isonitrile according to formula (2) comprising the steps:
(a) mixing A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) with
EtOAc,
(bl) adding triethylamine to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) in EtOAc
(b2) adding the propylphosphonic acid anhydride (III).
In an even more preferred embodiment, the process for preparing (3,3-difluorocyclo- butyl)isonitrile according to formula (2) comprises the steps:
(a) mixing A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) with
EtOAc,
(bl) adding triethylamine (II) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) in EtOAc at a temperature Tia selected from 0°C to 30°C,
(b2) adding the propylphosphonic acid anhydride (III) at a temperature Tib selected from 0°C to 30 °C and subsequently
(b3) heating the mixture to T2 selected from above 30°C to 77°C.
In an embodiment, the process for preparing ivosidenib according to formula (4) comprises the steps
(i) preparing (3,3-difluorocyclobutyl)isonitrile according to formula (2) by the process according to any one of claims 1 to 5,
(ii) reacting the (3,3-difluorocyclobutyl)isonitrile according to formula (2) with 2-chlorobenzaldehyde, 3 -amino-5 -fluoropyri dine, and L-pyroglutamic acid to obtain the compound according to formula (3), and
(iii) reacting the compound according to formula (3) with a compound selected from 2-bromo-4-cyano-pyridine, 4-cyano-2-fluoro-pyridine, 4-cyano-2-iodo-pyridine, and (4-cyano-2-pyridinyl)-trifluoromethanesulfonate, and purifying to obtain ivosidenib according to formula (4).
This reaction can be referred to as a Ugi one-pot reaction. This reaction is a four component reaction (U-4CR), wherein the components comprise an aldehyde/ketone (2- chlorobenzaldehyde), an amine (3-amino-5-fluoropyridine), a carboxylic acid (L-pyro glutamic acid) and an isonitrile functional group ((3,3-difluorocyclobutyl)isonitrile).
The purification in step (iii) comprises separating the diastereomers to obtain ivosidenib. The skilled person will know suitable techniques, such as high-performance liquid column chromatography (HPLC) or recrystallization from suitable solvents, to obtain ivosidenib as the desired diastereomer.
The reaction in step (ii) with a compound selected from 2-bromo-4-cyano-pyridine, 4- cyano-2-fluoro-pyridine, 4-cyano-2-iodo-pyridine, and (4-cyano-2-pyridinyl)-trifluoro- methanesulfonate, is a metal-catalyzed cross coupling reaction, e.g. a Buchwald- Hartwig coupling. Suitable reaction conditions, base, ligand and metal catalyst are known to the person skilled in the art. It is preferred that the metal catalyst is a
palladium catalyst and that the ligand is a sterically hindered phosphine ligand, preferably a dialkylbiaryl phosphine, dppf (l, l'-bis(diphenylphosphino)ferrocene) or XantPhos ligand (4,5-bis(diphenylphosphino)-9,9-dimethylxanthene). It is even more preferred that the metal catalyst is Pd2(dba)3 and the ligand is XantPhos.
In a preferred embodiment, the process for preparing the compound of formula (3) and the process for preparing ivosidenib according to formula (4) comprises the steps
(i) preparing (3,3-difluorocyclobutyl)isonitrile according to formula (2) by the process of the present invention and reacting the 3,3-difluorocyclobutyl)isonitrile according to formula (2) prepared in step (i) in-situ in step (ii) to obtain the compound of formula (3) in a one-pot process.
It is to be understood that in-situ and one-pot refer to a process wherein either both step (i) and step (ii) are performed in the same reaction vessel and only the additional reactants needed in step (ii) are further added to the reaction vessel or the 3,3-difluorocyclobutyl)isonitrile prepared in step (i) is obtained as a crude product by routine work-up and directly used in step (ii) without further purification by e.g. filtration or column chromatography.
Example
A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de was dissolved in EtOAc and TEA was added at 5°C. Propylphosphonic acid anhydride (III) (solution in EtOAc, 50 vol.-%) was added dropwise. After complete addition, the reaction was heated to reflux (77°C) until no amide was detected. The solution was transferred to a separating funnel and water was added. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic solvents were removed in vacuo to obtain the product as an oil. This material was used for the next step without further purification.
Claims
1. Process for preparing (3,3-difluorocyclobutyl)isonitrile according to formula (2)
comprising the steps:
(a) mixing A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1)
with an aprotic solvent (I) and
(b) reacting the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) with propylphosphonic acid anhydride (III) in the presence of a tertiary amine base (II).
2. The process of claim 1, wherein step (b) comprises the steps of
(bl) adding the tertiary amine base (II) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) in an aprotic solvent (I) and subsequently
(b2) adding the propylphosphonic acid anhydride (III).
3. The process of claim 1 or 2, wherein the tertiary amine base (II) is selected from the group consisting of triethylamine, di -/.vo-propy 1 ethyl am i ne, DBU, DABCO, quinuclidine and mixtures thereof.
4. The process of any one of claims 1 to 3, wherein the aprotic solvent (I) is selected from the group consisting of EtOAc, THF, acetonitrile, 1,4-dioxane, DMF, DMA and mixtures thereof.
5. The process of any one of claims 1 to 4, wherein step (b) further comprises:
adding the at least one tertiary amine base and/or the propylphosphonic acid anhydride (III) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form a i de according to formula (1) at a temperature Ti selected from -78°C to 30°C and subsequently heating the mixture to T2 selected from above 30°C to 77°C.
6. The process of any one of claims 1 to 5 comprising the steps:
(a) mixing A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) with
EtOAc,
(bl) adding triethylamine (II) to the A -(3 , 3 -di fl uorocy cl ob uty 1 )form am i de according to formula (1) in EtOAc at a temperature Tia selected from 0°C to 30°C,
(b2) adding the propylphosphonic acid anhydride (III) at a temperature Tib selected from 0°C to 30 °C and subsequently
(b3) heating the mixture to T2 selected from above 30°C to 77°C.
7. Use of propylphosphonic acid anhydride (III) for preparing (3,3-difluorocyclo- butyl)isonitrile according to formula (2), A - J 1 -(2-chl orophenyl )-2-[(3 , 3 -di fl uorocy cl o- butyl)amino]-2-oxo-ethyl}-N-(5-fluoro-3-pyridyl)-(S)-5-oxo-pyrrolidine-2-carboxamide according to formula
8. Process for preparing the compound of formula (3) comprising the steps
(i) preparing (3,3-difluorocyclobutyl)isonitrile according to formula (2) by the process according to any one of claims 1 to 6 and
(ii) reacting the (3,3-difluorocyclobutyl)isonitrile according to formula (2) with 2-chlorobenzaldehyde, 3 -amino-5 -fluoropyri dine and L-pyroglutamic acid to obtain the compound according to formula (3).
9. Process for preparing ivosidenib according to formula (4) comprising the step:
(i) preparing (3,3-difluorocyclobutyl)isonitrile according to formula (2) by the process according to any one of claims 1 to 6,
(ii) reacting the (3,3-difluorocyclobutyl)isonitrile according to formula (2) with 2-chlorobenzaldehyde, 3 -amino-5 -fluoropyri dine, and L-pyroglutamic acid to obtain the compound according to formula (3), and
(iii) reacting the compound according to formula (3) with a compound selected from 2-bromo-4-cyano-pyridine, 4-cyano-2-fluoro-pyridine, 4-cyano-2-iodo-pyridine, and (4-cyano-2-pyridinyl)-trifluoromethanesulfonate and purifying to obtain ivosidenib according to formula (4).
10. The process according to claim 8 or claim 9, wherein the (3,3-difluorocyclo- butyl)isonitrile according to formula (2) prepared in step (i) is reacted in-situ in step (ii) to obtain the ivosidenib according to formula (4) in a one-pot process.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18215451.8 | 2018-12-21 | ||
| EP18215451 | 2018-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2020127887A1 true WO2020127887A1 (en) | 2020-06-25 |
Family
ID=64900813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2019/086549 WO2020127887A1 (en) | 2018-12-21 | 2019-12-20 | Process for the preparation of an intermediate product of ivosidenib |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2020127887A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021026436A1 (en) * | 2019-08-08 | 2021-02-11 | Agios Pharmaceuticals, Inc. | A method for preparing ivosidenib and an intermediate thereof |
| WO2022126947A1 (en) * | 2020-12-18 | 2022-06-23 | 新发药业有限公司 | Environmentally friendly preparation method for substituted isonitrile compound |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005070879A1 (en) * | 2004-01-26 | 2005-08-04 | Clariant Produkte (Deutschland) Gmbh | Method for producing nitriles and isonitriles by using dehydration reactors with propanephosphonic acid anhydrides |
| WO2013107405A1 (en) * | 2012-01-19 | 2013-07-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2013107291A1 (en) | 2012-01-19 | 2013-07-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
-
2019
- 2019-12-20 WO PCT/EP2019/086549 patent/WO2020127887A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005070879A1 (en) * | 2004-01-26 | 2005-08-04 | Clariant Produkte (Deutschland) Gmbh | Method for producing nitriles and isonitriles by using dehydration reactors with propanephosphonic acid anhydrides |
| WO2013107405A1 (en) * | 2012-01-19 | 2013-07-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2013107291A1 (en) | 2012-01-19 | 2013-07-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
Non-Patent Citations (2)
| Title |
|---|
| JANETA POPOVICI-MULLER ET AL: "Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers", ACS MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 4, 19 January 2018 (2018-01-19), pages 300 - 305, XP055543764, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.7b00421 * |
| POPOVICI-MULLER, J. ET AL.: "Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers - Supporting Information", ACS MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 4, 19 January 2018 (2018-01-19), pages 1 - 32, XP055543906, ISSN: 1948-5875, DOI: 10.1021/acsmedchemlett.7b00421 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021026436A1 (en) * | 2019-08-08 | 2021-02-11 | Agios Pharmaceuticals, Inc. | A method for preparing ivosidenib and an intermediate thereof |
| WO2022126947A1 (en) * | 2020-12-18 | 2022-06-23 | 新发药业有限公司 | Environmentally friendly preparation method for substituted isonitrile compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7398436B2 (en) | Methyl 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7 ] Annelene-2-carboxylate salt and method for producing the same | |
| CA2914381A1 (en) | An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy]propyl]adenine | |
| KR20190057437A (en) | Lysin-glutamic acid dipeptide derivatives | |
| WO2020127887A1 (en) | Process for the preparation of an intermediate product of ivosidenib | |
| KR20060121889A (en) | Process for preparing 2-oxo-1-pyrrolidine derivatives | |
| WO2017118928A1 (en) | Process for the separation of diastereomers of tenofovir alafenamide | |
| Liu et al. | 2-Chlorotetrafluoroethanesulfinamide induced asymmetric vinylogous Mannich reaction | |
| DK2958893T3 (en) | Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide | |
| EP3082801A1 (en) | An advanced and cost-effective process for preparing highly pure vildagliptin | |
| JP2019534299A (en) | Process for producing (S) -N1- (2-aminoethyl) -3- (4-alkoxyphenyl) propane-1,2-diamine trihydrochloride | |
| CN113121549B (en) | Method for stereoselectively synthesizing chiral lactone, chiral compound and application thereof | |
| JP6483145B2 (en) | Catalytic hydrogenation to produce amines from amide acetals, ketene-N, O-acetals, or ester imides | |
| Abiko et al. | Highly efficient resolution of benzopyrano [4, 3-c] isoxazolidine derivatives: Versatile chiral auxiliaries for asymmetric alkylation | |
| CN105461656A (en) | Novel process for preparation of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl] piperazine | |
| JP3843152B2 (en) | Process for producing 4-alkoxy-1,1,1-trifluoro-3-buten-2-one | |
| JP2017014109A (en) | Manufacturing method of optically active 2,6-dimethyl tylosin derivative | |
| JP2008007457A (en) | POST-TREATMENT METHOD OF beta-HYDROXYCARBONYL COMPOUND | |
| CN102417497B (en) | Preparation method of optically active 1-indenone-3-acetate compound | |
| ES2214311T3 (en) | SUBSTITUTED CYCLOPENTENS, ITS PREPARATION AND ITS USE FOR CHIRAL ANDAMIOS | |
| JP3252484B2 (en) | Method for producing 4,5-dihydro [1,2,4] triazolo [4,3-a] quinoxaline derivative | |
| JP2752593B2 (en) | Process for producing (-)-3 (S) -methylpyridobenzoxazinecarboxylic acid derivative and intermediate thereof | |
| EP3898598A1 (en) | Method for producing (5s)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4h-isoxazol-3-yl]-2-methyl-benzoic acid | |
| KR20070113272A (en) | Pyroglutamate salts and their use in the optical resolution of intermediates for the synthesis of dextrocetirizine and levocetirizine | |
| US20180093987A1 (en) | Improved process for preparing idelalisib | |
| JP3808931B2 (en) | Optically active 4,5-diphenyl-1,3-dialkyl-2-halogenoimidazolinium halogenide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19832937 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 19832937 Country of ref document: EP Kind code of ref document: A1 |